(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 November 2011 (03.11.2011)

PCT

(10) International Publication Number
WO 2011/134944 A3

(51) International Patent Classification:
A61K 9/107 (2006.01) *A61K 31/57* (2006.01)
A61K 9/00 (2006.01)

(21) International Application Number:
PCT/EP2011/056548

(22) International Filing Date:
26 April 2011 (26.04.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/327,963	26 April 2010 (26.04.2010)	US
61/327,968	26 April 2010 (26.04.2010)	US
61/327,959	26 April 2010 (26.04.2010)	US
10161029.3	26 April 2010 (26.04.2010)	EP
10161034.3	26 April 2010 (26.04.2010)	EP
10161032.7	26 April 2010 (26.04.2010)	EP
61/424,411	17 December 2010 (17.12.2010)	US
61/424,402	17 December 2010 (17.12.2010)	US
61/424,407	17 December 2010 (17.12.2010)	US
10195766.0	17 December 2010 (17.12.2010)	EP
10195764.5	17 December 2010 (17.12.2010)	EP
10195760.3	17 December 2010 (17.12.2010)	EP

(71) Applicant *(for all designated States except US)*: **BESINS HEALTHCARE LUXEMBOURG SARL** [LU/LU]; 67, Boulevard Grande-Duchesse Charlotte, LU-1331 Luxembourg (LU).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **PICKERSGILL, Laura** [GB/BE]; 33 Avenue des Villas, BE-1060 Brussels (BE). **DI HOISER, Eva-Maria** [AT/AT]; Hitzendorf 90, AT-8151 Hitzendorf (AT). **ACHLEITNER, Georg** [AT/AT]; Am Langedelwehr 32, AT-8010 Graz (AT).

(74) Agent: **VAN WESTENBRUGGE, Andre**; Nederlandsch Octrooibureau, J.W. Frisolaan 13, NL-2517 JS The Hague (NL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
9 February 2012

WO 2011/134944 A3

(54) Title: LOW-OIL PHARMACEUTICAL EMULSION COMPOSITIONS COMPRISING PROGESTOGEN

(57) Abstract: The invention relates to a sterile, ready-to-use, pharmaceutical oil-in-water emulsion composition for parenteral administration comprising: · 0.015 to 0.5% wt./vol progesterone; • 0.5 to 10%) wt./vol. oil, wherein the oil comprises at least 85% wt./wt. triglyceride; • 0.0425 to 4.1% wt./vol. phospholipid; • 80-99.4%) wt./vol. aqueous medium; wherein the composition has an osmolality in the range of 200-1000 mOsm/kg. The invention further relates to the use of the aforementioned composition in therapeutic or prophylactic treatment, said treatment comprising intravenous administration of the pharmaceutical emulsion.